Alpha-1 Biologics, LLC

Other

The Institute for Human Genetics and Biochemistry

Ronald Winston

Cynthia L Bristow

A method for increasing the number of CD4+ T-lymphocytes in the serum of a subject in need of such treatment comprising administering to the subject a pharmaceutical composition comprising an amount of an L-isomer of β-lactam effective to increase the number of CD4+ T-lymphocytes in said patient's serum.

Therapeutic use of levorotatory β-lactams in hematopoiesis, immuno-oncology therapy, and regulation of lipoprotein and apolipoprotein levels

A method for increasing the number of CD4+ T-lymphocytes in the serum of a subject in need of such treatment comprising administering to the subject a pharmaceutical composition comprising an amount of an L-isomer of &#x3b2;-lactam effective to increase the number of CD4+ T-lymphocytes in said patient's serum.

Therapeutic use of levorotatory &#x3b2;-lactams in hematopoiesis, immuno-oncology therapy, and regulation of lipoprotein and apolipoprotein levels

Therapeutic use of tromethamine salt of L-ampicilline in hematopoiesis, immuno-oncology therapy, and regulation of lipoprotein and apolipoprotein levels

A previously unrecognized fundamental property of &#x3b1;PI is to regulate the phenotypic composition of circulating and tissue-associated cells derived from hematopoietic stem cells. The present invention comprises screening for various unmodified and modified &#x3b1;PI's which are useful in the treatment of abnormalities in the number of cells of myeloid or lymphoid lineage that are associated with Human Immunodeficiency Virus-1 (HIV-1) infection, microbial infection, leukemia, solid tumor cancers, atherosclerosis, autoimmunity, stem cell transplantation, organ transplantation, and other diseases affected by cells of the immune system. The interaction of &#x3b1;PI with its receptors, cell surface Human Leucocyte Elastase (HLEcs) and Lipoprotein Receptor-related Protein (LRP), influences the level of cells of different lineages. Genetic and proteolytic modification of &#x3b1;PI is used to target these receptors to increase or decrease specific cell populations, as needed, in the various disease states.

Therapeutic use for &#x3b1;proteinase inhibitor in hematopoiesis

Pharmaceutical composition containing the tromethamine salt of L-ampicillin

A previously unrecognized fundamental property of &#x3b1;Proteinase Inhibitor (&#x3b1;PI) is to regulate the phenotypic composition of circulating and tissue-associated cells derived from hematopoietic stem cells. The present invention comprises screening for various unmodified and modified &#x3b1;PI's which are useful in the treatment of abnormalities in the number of cells of myeloid or lymphoid lineage that are associated with HIV-1 infection, microbial infection, leukemia, solid tumor cancers, atherosclerosis, autoimmunity, stem cell transplantation, organ transplantation, and other diseases affected by cells of the immune system. The interaction of &#x3b1;PI with its receptors, Human Leukocyte Elastase Cell Surface (HLE) and Low Density Lipoprotein-Receptor Related Protein (LRP), influences the level of cells of different lineages. Genetic and proteolytic modification of &#x3b1;PI is used to target these receptors to increase or decrease specific cell populations, as needed, in the various disease states.

Therapeutic use for ALPHA1 proteinase inhibitor in hematopoiesis

In order to accurately and reliably quantitate HLE on the plasma membranes of the lymphocytes and mononuclear phagocytes, a test sample containing the lymphocytes and mononuclear phagocytes is initially treated with a first antiserum specific for CD4 receptors on the plasma membrane or with a second antiserum specific for chemokine receptors on the plasma membrane. Once the CD4 or chemokine receptors have been rendered non-reactive (competitive) relative to the HLE receptors (also 'binding sites') on the plasma membrane, the test sample is contacted with an immunoreagent specific for interaction with one or more of the HLE receptors on the plasma membranes of the lymphocytes and mononuclear phagocytes. The immunoreagent forms a complex with the HLE binding sites and produces a characteristic physical change in the lymphocytes and mononuclear phagocytes that can be monitored by anyone of a number of standard techniques, (e.g., confocal laser scanning microscopy and flow cytometry).

Detection of surface-associated human leukocyte elastase

In order to accurately and reliably quantitate HLE on the plasma membranes of the lymphocytes and mononuclear phagocytes, a test sample containing the lymphocytes and mononuclear phagocytes is initially treated with a first antiserum specific for CD4 receptors on the plasma membrane or with a second antiserum specific for chemokine receptors on the plasma membrane. Once the CD4 or chemokine receptors have been rendered non-reactive (competitive) relative to the HLE receptors (also 'binding sites') on the plasma membrane, the test sample is contacted with an immunoreagent specific for interaction with one or more of the HLE receptors on the plasma membranes of the lymphocytes and mononuclear phagocytes. The immunoreagent forms a complex with the HLE binding sites and produces a characteristic physical change in the lymphocytes and mononuclear phagocytes that can be monitored by any one of a number of standard techniques, (e.g., confocal laser scanning microscopy and flow cytometry).

Growing community of inventors

Long Beach, NY, United States of America

Cynthia L Bristow